These experimental data are supported by reports from the clinic that patients taking EGFR inhibitors (i.e., cetuximab, erlotinib, gefitinib) for the treatment of certain cancers have an increased incidence of corneal perturbations, including punctate keratopathy, dry eye, blepharitis, conjunctivitis, and trichiasis [35,36,59,60,61]. This evidence concerns the gene EGFR and cancer.